Novelty in Inflammation and Immunomodulation in Migraine
Authors:
- 9 October 2019
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 25 (27) , 2919-2936
Abstract
Background.: Migraine is a diffuse and disabling disease. Its pathophysiology is complex and involves both central and peripheral dysfunctions.Objective.: This review will discuss the pathogenesis of migraine from the origin of the neuro-inflammatory theory, to the modern pathophysiological model and the latest therapies.Methods.: PUBMED and EMBASE (up to May 2019) were searched for: migraine, inflammation, immunomodulation. An additional search was carried out from the bibliography of previous review articles.Results.: Migraine was thought to be mainly a vascular disorder, according to the so-called “vascular theory”. Based on animal models, a new hypothesis called “the neuro-inflammatory” was conceived at the end of the 20th century. The growing knowledge about the trigeminovascular system and its role in the inflammatory-pain pathway, allowed to identify other specific neurotransmitters, such as the Calcitonin Gene-Related Peptide and Pituitary Adenylate Cyclase-Activating Peptide. Evidence was provided that the inflammatory-pain system could become sensitised and, due to this sensitisation, the pain could also perpetuate, even in the absence of any triggers of the migraine attack. At last, brain immune cells modification during cortical spreading depression in migraine was demonstrated, along with the existence and function of the glymphatic system. The better comprehension of the immune system abnormalities allowed the development of new immunomodulating drugs: the monoclonal antibodies against the CGRP or the CGRP receptor. Moreover, new insights into the molecular mechanism of CGRP, and the function of C-fibres and Aδ-fibres, highlighted the mechanism of action of Botulinum Toxin type A in the treatment of chronic migraine.Keywords
This publication has 132 references indexed in Scilit:
- Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide: IUPHAR Review 1British Journal of Pharmacology, 2012
- Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38Cephalalgia, 2012
- Altered functional magnetic resonance imaging resting‐state connectivity in periaqueductal gray networks in migraineAnnals of Neurology, 2011
- Properties of a general PK/PD model of antibody-ligand interactions for therapeutic antibodies that bind to soluble endogenous targetsmAbs, 2010
- CGRP function‐blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the ratBritish Journal of Pharmacology, 2008
- Modulation of Meningeal Nociceptors Mechanosensitivity by Peripheral Proteinase-Activated Receptor-2: The Role of Mast CellsCephalalgia, 2008
- Sensitization and Activation of Intracranial Meningeal Nociceptors by Mast Cell MediatorsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Mast cell degranulation activates a pain pathway underlying migraine headachePain, 2007
- Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cellsBiochemical and Biophysical Research Communications, 1989
- Adrenergic, Cholinergic and Peptidergic Nerve Fibres in Dura Mater Involvement in Headache?Cephalalgia, 1981